Hydroxyzine Use in Patients with End-Stage Renal Disease

Introduction to Hydroxyzine Risks

• Hydroxyzine should be used with extreme caution in patients with end-stage renal disease (ESRD) due to increased risk of QT prolongation and CNS side effects, and dose reduction is strongly recommended if used at all.

Alternative Therapies for Anxiety Management

• The American Heart Association recommends considering SSRIs, particularly sertraline, as a safer alternative for anxiety management in ESRD patients, as they have been extensively studied and appear to have a lower risk of QTc prolongation than other options 1
• Mirtazapine has been shown to be safe in cardiovascular disease and offers additional benefits for sleep and appetite stimulation in ESRD patients 1

Monitoring and Precautions

• If hydroxyzine must be used in ESRD patients, it is recommended to obtain a baseline ECG to assess QTc interval, monitor for signs of excessive sedation, confusion, or other CNS effects, check electrolytes regularly and correct abnormalities, avoid concomitant use of other QT-prolonging medications, and use the lowest effective dose for the shortest duration possible.

Treatment of Allergic Reactions or Pruritus

• Second-generation antihistamines may have a better safety profile than hydroxyzine in ESRD patients for the treatment of allergic reactions or pruritus.